{"url_path":"/sec/rvmd/8-k/2026-06-22/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1628171/0001193125-26-276718-index.html","accession_number":"0001193125-26-276718","cik":"0001628171","ticker":"RVMD","issuer_name":"Revolution Medicines, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1628171/0001193125-26-276718-index.html","primary_entity_key":"0001628171","primary_entity_name":"Revolution Medicines, Inc."},"word_count":134,"has_tables":true,"body_markdown":"Item 5.02\n\nDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the “Company”) of his intent to retire from his employment with the Company effective as of January 4, 2027. Dr. Kelsey will transition from his role as the Company’s president, research and development to a new position as senior advisor to the chief executive officer effective as of July 1, 2026.\n\nUpon his retirement from the Company, Dr. Kelsey will be eligible to receive certain benefits under the Company’s retirement policy for equity awards.\n\nThe Company currently contemplates appointing Dr. Kelsey to its board of directors (the “Board”) effective as of his retirement on January 4, 2027, subject to Board approval."}